What Repligen (NASDAQ: RGEN) plans to pay for each BioLife share
Repligen (RGEN) filed an amended Form S-4 to register shares for its acquisition of BioLife Solutions. The deal offers $11.25 in cash plus 0.1442 Repligen shares per BioLife share, pending approvals. The merger is subject to shareholder and regulatory approvals, with a special meeting scheduled for October 5, 2026. The exchange ratio is fixed, but the value of the share portion will fluctuate with Repligen's stock price.
How this was made
The 30-second read
Why it matters
The merger terms set a clear valuation for BioLife and introduce dilution risk for Repligen, creating immediate arbitrage opportunities.
Market read
Both stocks will react to the disclosed terms; traders can position for merger arbitrage.
What to watch
Potential dilution to Repligen shareholders and appraisal rights for BioLife holders could affect pricing.
Background
Repligen announced the detailed terms of its two‑step merger with BioLife, including cash and stock components.
Ticker impact
Repligen filed an amended Form S‑4 detailing the cash and stock consideration for its pending merger with BioLife.
Repligen may trade lower pending dilution; upside if merger completes at premium.
The disclosed exchange ratio ties Repligen's stock price to the deal value, creating immediate arbitrage considerations.
BioLife Solutions received a merger offer of $11.25 cash plus 0.1442 Repligen shares per BioLife share.
BioLife likely to trade near the implied value of the offer, with upside if premium perceived.
The terms are newly disclosed and set a clear valuation floor for the stock.
Market effects
Consolidation in the biopharma services sector may pressure peers.
US biotech market sees increased M&A activity.
Limited to biotech investors; no broad market effect.
Counterpoint
If regulatory or antitrust hurdles arise, the deal could collapse, making the offer unattractive.
Key entities
- CompanyRepligen Corporation
US‑listed biotech firm proposing the merger.
- CompanyBioLife Solutions, Inc.
Target company receiving the merger offer.
